Sales of Gilead’s COVID-19 drug top $800 million
July 29, 2021 at 16:45 PM EDT
Gilead Sciences Inc. late Thursday swung to profit and reported rising sales thanks to its COVID-19 drug, but a revenue drop from two of its HIV drugs and ongoing concerns about the pandemic dragged the stock lower.
